SIRPA and cancer: Supporting this notion, our investigations show that the αvβ3/CD47 interfering peptide PSFL‐NK13 disrupts the αvβ3/CD47–SIRPα axis without inducing the hemolytic side effects associated with CD47 antibodies (Figures 6, 7, 8), presenting a promising avenue for safe and effective cancer immunotherapy.